ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML Under …

Insights from 2023 ASH Annual Meeting

S. Urrutia

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

ASH 2023 Insights: "Venetoclax Improves Response Rates But Not Survi…

Insights from 2023 ASH Annual Meeting

D. Tremblay

SOHO 2021 Update on CMML Overview of the Most Recent Data

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

G. Montalban-Bravo

2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

G. Garcia-Manero

MD Anderson Immune Checkpoint Based Approaches in AML & MDS: Which C…

Naval Daver

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit t…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Tyner

How to Calculate Risk in MDS Patients?

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decre…

University of Miami's 2nd Biennial Miami Leukemia Symposium

A. Verma

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

A. Mishra

In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

R. Komrokji

Frontline Therapies in MDS: Leveling Lower-risk MDS

University of Miami's 2nd Biennial Miami Leukemia Symposium

M. Sekeres

MDS/MPN Overlap Through Interactive Case Based Discussion: Overview …

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

A. Kuykendall

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…

University of Miami's 2nd Biennial Miami Leukemia Symposium

T. Graubert

Relapse After Allo HSCT - Treatment Strategies and Overview of Relat…

Indy Hematology Review

R. Childs

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…

Cleveland Clinic's 20th Annual ASH Review

H. Carraway

MDS/MPN: Senectus Ipsa Est Morbus (Disease of Old Age)?

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

M. Deininger

Chronic Myelomonocytic Leukemia: Define, Diagnosis, Prognostications…

Indy Hematology Review

A. Tefferi